<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; brands</title>
	<atom:link href="http://www.tapanray.in/tag/brands/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Do Drug Companies Now Need More Focus On The 5th &#8220;P&#8221; Of Marketing?</title>
		<link>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing</link>
		<comments>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/#comments</comments>
		<pubDate>Mon, 07 Mar 2022 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[4 Ps]]></category>
		<category><![CDATA[5th P]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driving]]></category>
		<category><![CDATA[Get Z]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[marketing-mix]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10665</guid>
		<description><![CDATA[Astute marketers understand that over several decades, the much-known phraseology &#8211; ‘marketing mix’, has remained the bedrock of marketing a product or a service. The ‘Father of Modern Marketing’ - Philip Kotler defined this terminology as the &#8220;the set of controllable variables that &#8230; <a href="http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Novel Marketing Pathways As Covid Mutants Keep Emerging</title>
		<link>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-novel-marketing-pathways-as-covid-mutants-keep-emerging</link>
		<comments>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/#comments</comments>
		<pubDate>Mon, 10 Jan 2022 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approvals]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[EUA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molnupiravir]]></category>
		<category><![CDATA[mutants]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[variants]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10634</guid>
		<description><![CDATA[The World’s battle against wave after wave unsettling onslaught of Coronavirus on human lives and livelihood continues, since December 2019. The first wave was triggered by the novel Covid-19 from Wuhan in China, the second by its deadly – Delta variant, &#8230; <a href="http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing: The New Normal: Challenges of Change</title>
		<link>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-the-new-normal-challenges-of-change</link>
		<comments>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/#comments</comments>
		<pubDate>Mon, 28 Jun 2021 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[challenges of change]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[end-point]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price-point]]></category>
		<category><![CDATA[Problem-solving]]></category>
		<category><![CDATA[purpose-driven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resilience]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10537</guid>
		<description><![CDATA[A lot has changed in healthcare marketing prompted by the Covid pandemic. Apace with these, lots of old problems continue to remain very much the same. The aforesaid was observed in a recent article, published by WARC, on May 21, 2021. Although, &#8230; <a href="http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Purpose-Driven-Brands To Win Marketing Warfare In The New Reality</title>
		<link>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality</link>
		<comments>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/#comments</comments>
		<pubDate>Mon, 05 Oct 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[democratize]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[new reality]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven-brands]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[redefinition]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[warfare]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10286</guid>
		<description><![CDATA[As we navigate through the Covid days, the hope of somehow getting back to the pre-pandemic normal still lingers – notwithstanding a host of uncertainties in its way. The longing is driven by the hype of availability of scientifically proven, safe and &#8230; <a href="http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-purpose-driven-brands-to-win-marketing-warfare-in-the-new-reality/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping Rich Harvest With Orphan Drugs</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-orphan-drugs</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/#comments</comments>
		<pubDate>Mon, 21 Oct 2019 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[health for all]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[quid pro quo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich harvest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9752</guid>
		<description><![CDATA[A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access</title>
		<link>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access</link>
		<comments>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/#comments</comments>
		<pubDate>Mon, 09 Sep 2019 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Spirit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9701</guid>
		<description><![CDATA[For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. &#8230; <a href="http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Brand Building in a Changing Scenario: Thinking Outside the Box</title>
		<link>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box</link>
		<comments>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/#comments</comments>
		<pubDate>Mon, 18 Feb 2013 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1405</guid>
		<description><![CDATA[In this article, I shall explore unconventional ways of “Building sustainable Pharmaceutical Brands” thinking  outside the box, after quickly taking you through the “Challenges of Change” in the evolving dynamics of  the Indian branded generic market. A paradigm shift has &#8230; <a href="http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Differentiating Seven &#8216;Ps&#8217; of Marketing-Mix for Health Food Products &#8211; A strategic overview</title>
		<link>http://www.tapanray.in/differentiating-seven-ps-of-marketing-mix-for-health-food-products-a-strategic-overview/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=differentiating-seven-ps-of-marketing-mix-for-health-food-products-a-strategic-overview</link>
		<comments>http://www.tapanray.in/differentiating-seven-ps-of-marketing-mix-for-health-food-products-a-strategic-overview/#comments</comments>
		<pubDate>Mon, 17 May 2010 01:30:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['Ps]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Differentiating]]></category>
		<category><![CDATA[Food]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Mix]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[overview]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Seven]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=427</guid>
		<description><![CDATA[As estimated by Nicholas Hall the health food products market in India is currently around U.S.$ 1.3 Billion with a huge marketing potential. However, the marketing-mix for such groups of health food products will need to be crafted in an &#8230; <a href="http://www.tapanray.in/differentiating-seven-ps-of-marketing-mix-for-health-food-products-a-strategic-overview/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/differentiating-seven-ps-of-marketing-mix-for-health-food-products-a-strategic-overview/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
